Enzalutamide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB08899 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 69 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | prostate cancer/brain cancer susceptibility | KG + DL |
| 2 | prostate leiomyoma | KG + DL |
| 3 | Brenner tumor | KG + DL |
| 4 | fibroma of prostate | KG + DL |
| 5 | benign reproductive system neoplasm | KG + DL |
| 6 | male reproductive organ cancer | KG + DL |
| 7 | benign prostate phyllodes tumor | KG + DL |
| 8 | benign neoplasm of prostate | KG + DL |
| 9 | prostate neoplasm | KG + DL |
| 10 | prostate phyllodes tumor | KG + DL |
| 11 | nonpapillary renal cell carcinoma | KG + DL |
| 12 | palmoplantar keratoderma-sclerodactyly syndrome | KG + DL |
| 13 | female breast carcinoma | KG + DL |
| 14 | renal carcinoma | KG + DL |
| 15 | peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome | KG + DL |
| 16 | liposarcoma | KG + DL |
| 17 | renal cell carcinoma (disease) | KG + DL |
| 18 | renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions | KG + DL |
| 19 | unclassified renal cell carcinoma | KG + DL |
| 20 | renal cell carcinoma associated with neuroblastoma | KG + DL |
| 21 | ovarian myxoid liposarcoma | KG + DL |
| 22 | angiolipoma | KG + DL |
| 23 | endocrine-cerebro-osteodysplasia syndrome | KG + DL |
| 24 | renal pelvis carcinoma | KG + DL |
| 25 | HIV infectious disease | KG + DL |
| 26 | malignant prostate phyllodes tumor | KG + DL |
| 27 | familial spontaneous pneumothorax | KG + DL |
| 28 | simian immunodeficiency virus infection | KG + DL |
| 29 | feline acquired immunodeficiency syndrome | KG + DL |
| 30 | childhood kidney cell carcinoma | KG + DL |
| 31 | collecting duct carcinoma | KG + DL |
| 32 | chromophobe renal cell carcinoma | KG + DL |
| 33 | clear cell renal carcinoma | KG + DL |
| 34 | sarcomatoid renal cell carcinoma | KG + DL |
| 35 | acquired cystic disease-associated renal cell carcinoma | KG + DL |
| 36 | cystic renal cell carcinoma | KG + DL |
| 37 | kidney medullary carcinoma | KG + DL |
| 38 | estrogen-receptor negative breast cancer | KG + DL |
| 39 | Ehrlich tumor carcinoma | KG + DL |
| 40 | estrogen-receptor positive breast cancer | KG + DL |
| 41 | hormone-resistant breast carcinoma | KG + DL |
| 42 | multilocular clear cell renal cell carcinoma | KG + DL |
| 43 | CMM7 | KG + DL |
| 44 | melanoma | KG + DL |
| 45 | bilateral breast carcinoma | KG + DL |
| 46 | renal pelvis adenocarcinoma | KG + DL |
| 47 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | KG + DL |
| 48 | pediatric leptomeningeal melanoma | KG + DL |
| 49 | epithelioid cell uveal melanoma | KG + DL |
| 50 | Mitchell-Riley syndrome | KG + DL |
(Showing top 50 of 69 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.